Objective assessment of neurotoxicity while shifting from carbamazepine to oxcarbazepine

Acta Neurologica Scandinavica

Volumn 109, Issue 5, 2004, Pages 324-329

  Clemens, B ^a   Menes A ^a   Nagy, Z ^a  

^a Kenezy Korhaz Rendelointezet   (Hungary)

Author keywords

Carbamazepine; Neurotoxicity; Oxcarbazepine

Indexed keywords

CARBAMAZEPINE; OXCARBAZEPINE;

ADULT; ALPHA RHYTHM; ARTICLE; BETA RHYTHM; CLINICAL TRIAL; COHORT ANALYSIS; DELTA RHYTHM; DRUG TOLERABILITY; ELECTROENCEPHALOGRAPHY; EVOKED AUDITORY RESPONSE; EVOKED BRAIN STEM RESPONSE; FEMALE; FOCAL EPILEPSY; HUMAN; MALE; MONOTHERAPY; NEUROLOGIC EXAMINATION; NEUROTOXICITY; SEIZURE; SPIKE WAVE; THETA RHYTHM;

ADULT; ANTICONVULSANTS; BRAIN STEM; CARBAMAZEPINE; CEREBRAL CORTEX; DRUG RESISTANCE; ELECTROENCEPHALOGRAPHY; EPILEPSIES, PARTIAL; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; FEMALE; FOURIER ANALYSIS; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PROSPECTIVE STUDIES; SIGNAL PROCESSING, COMPUTER-ASSISTED; SUBSTANCE WITHDRAWAL SYNDROME; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 19244366475     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-0404.2003.00234.x     Document Type: Article

References (41)

1. BILL PA, VIGOROUS U, POHLMANN H et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997;27:195-204.
2. GUERREIRO MM, VIGONIUS U, POHLMANN H et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997;27:205-13.
3. CHRISTE W, KRAMER G, VIGONIUS U et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997;26:451-60.
4. REINIKAINEN KJ, KERANEN T, HALONEN T, KOMULAINEN H, RIEKKINEN PJ. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987; 1:284-9.
5. DAM M, EKBERG R, LOYNING Y, WATIMO O, JAKOBSEN K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly dignosed, previously untreated epilepsy. Epilepsy Res 1989;3:70-6.
6. PELLOCK JM. Carbamazepine side effects in children and adults. Epilepsia 1987;28(Suppl. 3):S64-70.
7. TECOMA ES. Oxcarbazepine. Epilepsia 1999;40(Suppl. 5): S37-46.
8. SHORVON S. Oxcarbazepine: a review (Editorial). Seizure 2000;9:75-9.
9. WELLINGTON K, GOA KL. Oxcarbazepine. An update of its efficacy in the management of epilepsy. CNS Drugs 2001;15:137-63.
10. FRIIS ML, KRISTENSEN O, BOAS J et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993;87:224-7.
11. DAM M. Practical aspects of oxcarbazepine treatment. Epilepsia 1994;35(Suppl. 3):S23-5.
12. HOUTKOOPER MA, LAMMERTSMA A, MEYER JWA et al. Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine? Epilepsia 1987;28:693-8.
13. REYNOLDS EH. Mental effects of antiepileptic medication: a review. Epilepsia 1983;24(Suppl. 2):S85-95.
14. NOVELLY RA, SCHWARTZ MM, MATTSON RHZ, CRAMER JA. Behavioral toxicity associated with antiepileptic drugs: concepts and methods of assessment. Epilepsia 1986;27:331-40.
15. SOMMER JB, ZAHNER B, PAULI E, STEFAN H. Carbamazepine in patients with epilepsy: subjective complaints but no objective impairment of cognitive function. Epilepsia 1999;40(Suppl. 2):96.
16. ALDENKAMP AP. Effects of antiepileptic drugs on cognition. Epilepsia 2001;42(Suppl. 1):46-9.
17. MATTSON RH, CRAMER JA. Quantitative assessment of adverse drug effects. In: MEINARDI H et al. eds. Quantitative assessment in epilepsy care. New York: Plenum Press, 1993;123-35.
18. ADAMS RD, VICTOR M, ROPPER AH. Principles of neurology, 6th edn. New York: McGraw-Hill, 1997.
19. NUWER M, LEHMANN D, LOPES DA SILVA F, MATSUOKA S, SUTHERLING W, VIBERT J-F. IFCN guidelines for topographic and frequency analysis of EEGs and EPs. Report of an IFCN committee. Electroencephalogr Clin Neurophysiol 1994;91:1-5.
20. JOHN ER, PRICHEP LS. Principles of neurometric analysis of EEG and evoked potentials. In: NIEDERMEYER E, LOPES DA SILVA FH, eds. Electroencephalography. Basic principles, clinical applications and related fields, 3rd edn. Baltimore: Williams and Wilkins, 1993;989-1003.
21. KLIMESCH W, SCHIMKE H, LADURNER G, PFURTSCHELLER G. Alpha frequency and memory performance. J Psychophysiol 1990;4:381-90.
22. BAKER GA, CAMFIELD C, CAMFIELD P et al. Commission on outcome measurement in epilepsy, 1994-1997: final report. Epilepsia 1998;39:213-31.
23. BASAR E, SCHURMANN M, BASAR-EROGLU-C, KARAKAS-S. Alpha oscillations in brain functioning: an integrative theory. Int J Psychophysiol 1997;26:5-29.
24. KLIMESCH W. EEG alpha and theta oscillations reflect cognitive and memory performance: a review and analysis. Brain Res Rev 1999;29:169-95.
25. ZACCARA G, GANGEMI PF, PARIGI A, MASSI S, VALENZA T, MONZA GC. Effects of oxcarbazepine and carbamazepine of the central nervous system: computerized analysis of saccadic and smooth-pursuit eye movements. Acta Neurol Scand 1992;85:425-9.
26. HERRMANN WM, SCHAERER E. Pharmaco-EEG: computer EEG analysis to describe the projection of drug effects on a functional cerebral level in humans. In: LOPES DA SILVA FH, VAN STORM LEEUWEN W, RÉMOND A, eds. Handbook of electroencephalography and clinical neurophysiology (Revised Series), Vol. 2. Clinical application of computer analysis of EEG and other neurophysiological signals. Amsterdam: Elsevier, 1986;385-445.
27. MIYAUCHI T, ENDO K, YAMAGUCHI T, HAGIMOTO H. Computerized analysis of EEG background activity in epileptic patients. Epilepsia 1991;32:870-81.
28. DIAZ GF, VIRUÉS T, SAN MARTIN M et al. Generalized qEEG background abnormalities in localized symptomatic epilepsy. Electroencephalogr Clin Neurophysiol 1998;106: 501-7.
29. RIEKKINEN PJ, KALVIAINEN R, AIKIA M, PARTANEN J, SAKSA M, SIVENIUS J. Cognitive and electrophysiologic effects of vigabatrin and carbamazepine monotherapy. Epilepsia 1990;31:620.
30. MARCIANI MG, GIGLI GL, STEFANINI F et al. Effect of carbamazepine on EEG background activity and on interictal epileptiform abnormalities in focal epilepsy. Int J Neurosci 1993;70:107-16.
31. SALINSKY MC, OKEN BS, MORHEAD L. Intraindividual analysis of antiepileptic drugs effects on EEG background rhythms. Electroencephalogr Clin Neurophysiol 1994;90:186-193.
32. FROST JD, HRACHOVY RA, GLAZE DG, RETTIG GM. Alpha rhythm slowing during initiation of carbamazepine therapy: implications for future cognitive performance. J Clin Neurophysiol 1995;12:57-63.
33. TUUNAINEN A, NOUSIAINAN U, PILKE A, MERVAALA E, PARTANEN J, RIEKKINEN P. Spectral EEG during short-term discontinuation of antiepileptic medication in partial epilepsy. Epilepsia 1995;36:817-23.
34. SURVILLO W. Frequency of the alpha rhythm, reaction time and age. Nature 1961;191:823-4.
35. OSAKA M. Peak alpha frequency of EEG during a mental task: task difficulty and hemispheric differences. Psychophysiology 1984;21:101-5.
36. SALETU B, ANDERER P, KINSPERGER K, GRÜNBERGER J. Topographic brain mapping of EEG in neuropharmacology - Part II. Clinical applications (Pharmaco EEG imaging). Methods Find Exp Clin Pharmacol 1987;9:385-408.
37. RYSZ A, GAJDOWSKI K. Effect of phenytoin and carbamazepine on evoked potentials in patients with newly dignosed epilepsy. Part II. Brainstem auditory evoked potentials. Neurol Neurochir Pol 1996;6:971-9. (Abstract in English).
38. VAN DER MEYDEN CH, BARTEL RP, DE SOMMERS K et al. Effect of acute doses of controlled-release carbamazepine on clinical, psychomotor, electrophysiological, and cognitive parameters of brain function. Epilepsia 1992;33:335-42.
39. MERVAALA E, KERANEN T, TIIHONEN P, RIEKKINEN P. The effects of carbamazepine and sodium valproate on SEPs and BAEPs. Electroencephalogr Clin Neurophysiol 1987;68: 475-8.
40. FROMM GH. Effects of different classes of antiepileptic drugs on brain-stem pathways. Federation Proc 1985;44:2432-5.
41. VERMEULEN J, ALDENKAMP AP. Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Epilepsy Res 1995;22:65-95.